ICD-10 Impact: Desmoid Tumor Advances

EP: 1.Desmoid Tumors: Characteristics and Diagnosis Challenges

Now Viewing

EP: 2.ICD-10 Impact: Desmoid Tumor Advances

EP: 3.Imaging and Risks in Desmoid Tumors

EP: 4.Gene Expression in Desmoid Treatment

EP: 5.Multidisciplinary Care for Desmoid Tumors

EP: 6.NCCN Guidelines and Treatment Insights for Desmoid Tumors

EP: 7.Desmoid Tumor Treatment: Bridging Gaps Between Community and Academic Care

EP: 8.Strategic Desmoid Tumor Education and Access

EP: 9.Therapeutic Access and Emerging Treatments

EP: 10.Desmoid Tumors: Impact and Quality of Life

EP: 11.Managing Desmoid Tumor Challenges

EP: 12.Psychosocial Impact and Pain Management for Desmoid Tumors

EP: 13.Watchful Management and Patient Support for Desmoid Tumors

EP: 14.Empowering Desmoid Tumor Patients: Education and Resources

This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA; Tony Phillip, MD; Mrinal Gounder, MD; Ravin Ratan, MD, MEd; and Derek van Amerongen, MD, MS.

New location-specific International Statistical Classification of Diseases, Tenth Revision (ICD-10) codes for desmoid tumors became available in October 2022 after advocacy from the Desmoid Tumor Research Foundation. These codes will enable better understanding of desmoid tumor epidemiology, facilitating research and appropriate treatments. Previously, desmoid tumors were coded vaguely under “sarcoma,” losing critical information. The new codes provide needed specificity on incidence, prevalence, geographic distribution, and outcomes. This granularity also helps communicate with payers regarding appropriate care. However, the codes’ utility relies on accurate coding, especially at smaller institutions without professional coders. Overall, the new ICD-10 codes—though requiring diligent application—should improve desmoid tumor diagnosis, treatment, research, reimbursement, and, ultimately, patient outcomes.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.